Nurix Therapeutics Inc.

11.48
-0.08 (-0.69%)
At close: Apr 28, 2025, 3:59 PM
11.47
-0.09%
After-hours: Apr 28, 2025, 05:44 PM EDT

Company Description

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders.

The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer.

The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018.

The company was incorporated in 2009 and is headquartered in San Francisco, California.

Nurix Therapeutics Inc.
Nurix Therapeutics Inc. logo
Country United States
IPO Date Jul 24, 2020
Industry Biotechnology
Sector Healthcare
Employees 286
CEO Dr. Arthur T. Sands M.D., Ph.D.

Advertisement

Contact Details

Address:
1700 Owens Street
San Francisco, California
United States
Website https://www.nurixtx.com

Stock Details

Ticker Symbol NRIX
Exchange NASDAQ
Fiscal Year December - November
Reporting Currency USD
CIK Code 0001549595
CUSIP Number 67080M103
ISIN Number US67080M1036
Employer ID 27-0838048
SIC Code 2834

Key Executives

Name Position
Dr. Arthur T. Sands M.D., Ph.D. Chief Executive Officer, President & Director
Dr. Christine Ring J.D., Ph.D. Chief Legal Officer, Secretary & Chief Compliance Officer
Johannes Van Houte Chief Financial Officer
Christopher B. Phelps Ph.D. Senior Vice President & Head of Early Drug Discovery
Dr. Arthur Weiss M.D., Ph.D. Founder & Member of Scientific Advisory Board
Dr. Gwenn M. Hansen Ph.D. Chief Scientific Officer
Dr. Jason Kantor Ph.D. Chief Business Officer
Dr. John Kuriyan Ph.D. Founder & Member of Scientific Advisory Board
Dr. Pasit Phiasivongsa Ph.D. Chief Technical Officer
Rita Kwong Senior Accounting Manager

Latest SEC Filings

Date Type Title
Apr 23, 2025 SCHEDULE 13G/A [Amend] Filing
Apr 08, 2025 10-Q Quarterly Report
Apr 08, 2025 8-K Current Report
Mar 28, 2025 DEFA14A Filing
Mar 28, 2025 ARS Filing
Mar 28, 2025 DEF 14A Filing
Mar 13, 2025 4 Filing
Mar 13, 2025 3 Filing
Mar 13, 2025 8-K Current Report
Mar 03, 2025 4 Filing